PCI Biotech Holding ASA (LTS:0JGL) Scaled Net Operating Assets: -0.03 (As of Jun. 2025)


What is PCI Biotech Holding ASA Scaled Net Operating Assets?

PCI Biotech Holding ASA LTS:0JGL Scaled Net Operating Assets is -0.03 as of Jun. 2025. The stock has 1 warning sign investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PCI Biotech Holding ASA's operating assets for the quarter that ended in Jun. 2025 was kr4.91 Mil. PCI Biotech Holding ASA's operating liabilities for the quarter that ended in Jun. 2025 was kr5.73 Mil. PCI Biotech Holding ASA's Total Assets for the quarter that ended in Dec. 2024 was kr31.22 Mil. Therefore, PCI Biotech Holding ASA's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2025 was -0.03.

PCI Biotech Holding ASA Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Scaled Net Operating Assets Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.02 -0.02 -0.07

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 -0.03 0.04 -0.08 -0.03

LTS:0JGL vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Scaled Net Operating Assets falls into.


PCI Biotech Holding ASA Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PCI Biotech Holding ASA's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(4.522-7.426)/44.05
=-0.07

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=31.215 - 26.693
=4.522

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=7.762 - 0 - 0.336
=7.426

PCI Biotech Holding ASA's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2025 )
=(Operating Assets (Q: Jun. 2025 )-Operating Liabilities (Q: Jun. 2025 ))/Total Assets (Q: Dec. 2024 )
=(4.906-5.726)/31.215
=-0.03

where

Operating Assets(Q: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=18.523 - 13.617
=4.906

Operating Liabilities(Q: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6.008 - 0 - 0.282
=5.726

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.03 mean?
PCI Biotech Holding ASA (LTS:0JGL) has a Scaled Net Operating Assets of -0.03 as of Jun. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Scaled Net Operating Assets too high?
PCI Biotech Holding ASA's current Scaled Net Operating Assets is -0.03.
How does PCI Biotech Holding ASA's Scaled Net Operating Assets compare to VRTX and REGN?
PCI Biotech Holding ASA's Scaled Net Operating Assets of -0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Scaled Net Operating Assets is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current Scaled Net Operating Assets of -0.03. The current Scaled Net Operating Assets is -0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current Scaled Net Operating Assets is -0.03 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.